Estrogen receptor α (ESR1) mutations are prevalent in patients with estrogen receptor (ER)-positive metastatic breast cancer treated with aromatase inhibitors, with particular mutations increasing the risk for more aggressive tumor biology, a study published in JAMA Oncology has shown.1

ESR1 mutations harbored by patients with metastatic breast cancer promote ligand-independent receptor activation and resistance to estrogen-deprivation therapy in preclinical models; however, the prevalence of these mutations and their effect on clinical outcomes is unclear.

For the study, investigators analyzed cell-free DNA from baseline plasma samples from 541 patients with metastatic breast cancer who participated in the phase 3 BOLERO-2 trial, which evaluated the efficacy and safety of exemestane plus everolimus vs exemestane plus placebo. All patients were postmenopausal women who had previously received an aromatase inhibitor.

Continue Reading

Results showed that 21.1% of the 541 evaluable patients had ESR1 mutation D538G and 13.3% harbored the Y537S mutation. Thirty patients had both.

Researchers found that both mutations were associated with worse overall survival. Patients with wild-type ESR1 had a median overall survival of 32.1 months (95% CI, 28.09-36.40); those with the D538G mutation had a median survival of 25.99 months (95% CI, 19.19-32.36); Y537S conferred a survival of 19.98 months (13.01-29.31); and having both mutations was associated with a median survival of 15.15 months (95% CI, 10.87-27.43).

The study further demonstrated that patients harboring the ESR1 mutation D538G derived a similar progression-free survival from the addition of everolimus to exemestane compared with those with wild-type ESR1.


1. Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer. JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]